REFRACTORY PTLD WITH DLBCL PHENOTYPE TREATED WITH CD19 CAR T-CELL THERAPY

被引：0
|
作者：
Whitman, Abbie [1 ]
Damodharan, Sudarshawn [1 ]
Capitini, Christian [1 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
160
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [41] CD19 CAR T-CELL CLINICAL OUTCOME IS ASSOCIATED WITH THE GUT MICROBIOME
    不详
    CANCER DISCOVERY, 2022, 12 (05) : 1182 - 1182
  • [42] CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up
    Mueller, Fabian
    Taubmann, Jule
    Bucci, Laura
    Wilhelm, Artur
    Bergmann, Christina
    Voelkl, Simon
    Aigner, Michael
    Rothe, Tobias
    Minopoulou, Ioanna
    Tur, Carlo
    Knitza, Johannes
    Kharboutli, Soraya
    Kretschmann, Sascha
    Vasova, Ingrid
    Spoerl, Silvia
    Reimann, Hannah
    Munoz, Luis
    Gerlach, Roman G.
    Schaefer, Simon
    Grieshaber-Bouyer, Ricardo
    Korganow, Anne-Sophie
    Farge-Bancel, Dominique
    Mougiakakos, Dimitrios
    Bozec, Aline
    Winkler, Thomas
    Kroenke, Gerhard
    Mackensen, Andreas
    Schett, Georg
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (08): : 687 - 700
  • [43] Lymphodepleting Chemotherapy before CD19 Directed CAR T-Cell Therapy: Are 3 Days Necessary?
    Geer, Marcus
    Kasha, Salena
    Frame, David
    Ghosh, Monalisa
    BLOOD, 2022, 140 : 3823 - 3824
  • [44] Tips on Choosing a CAR T-Cell Therapy in DLBCL
    Abramson, Jeremy S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (11) : 592 - 596
  • [45] Total Metabolic Tumor Volume (TMTV) correlates with treatment failure after CD19 CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
    Vercellino, L. S.
    Paillassa, J.
    Martineau, A.
    Chevret, S.
    Di Blasi, R.
    Bernard, S.
    De Kerviler, E.
    Meignin, V.
    Meignan, M.
    Merlet, P.
    Thieblemont, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S153 - S154
  • [46] CAR T-cell therapy for secondary CNS DLBCL
    Ahmed, Gulrayz
    Hamadani, Mehdi
    Shah, Nirav N.
    BLOOD ADVANCES, 2021, 5 (24) : 5626 - 5630
  • [47] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
  • [48] Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD
    McKenna, Marshall
    Epperla, Narendranath
    Ghobadi, Armin
    Liu, Jieqi
    Lazaryan, Aleksandr
    Ibrahim, Uroosa
    Jacobson, Caron A. A.
    Naik, Seema G. G.
    Nastoupil, Loretta
    Chowdhury, Sayan Mullick
    Voorhees, Timothy J. J.
    Jacobs, Miriam T.
    Farooq, Umar
    Osman, Keren
    Olszewski, Adam J. J.
    Ahmed, Sairah
    Evens, Andrew M. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (02) : 248 - 255
  • [49] CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy (vol 4, pg 3850, 2020)
    Thapa, B.
    Caimi, P. F.
    Ardeshna, K. M.
    Carlo-Stella, Carmelo
    BLOOD ADVANCES, 2020, 4 (19) : 4606 - 4606
  • [50] High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
    Gauthier, Jordan
    Chou, Cassie
    Hirayama, Alexandre V.
    Fiorenza, Salvatore
    Sheih, Alyssa
    Pender, Barbara S.
    Tinh-Doan Phi
    Steinmetz, Rachel
    Jamieson, Abby
    Kirchmeier, Delaney R.
    Di, Henna N.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    BLOOD, 2020, 136
12345